Purkiss Capital Advisors LLC Purchases 3,275 Shares of Prothena Corporation plc $PRTA

Purkiss Capital Advisors LLC grew its position in shares of Prothena Corporation plc (NASDAQ:PRTA) by 15.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,904 shares of the biotechnology company’s stock after buying an additional 3,275 shares during the quarter. Purkiss Capital Advisors LLC’s holdings in Prothena were worth $151,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Nordea Investment Management AB lifted its holdings in shares of Prothena by 1.2% during the 2nd quarter. Nordea Investment Management AB now owns 311,605 shares of the biotechnology company’s stock valued at $1,916,000 after buying an additional 3,618 shares during the period. Public Employees Retirement System of Ohio bought a new position in shares of Prothena during the 2nd quarter valued at $256,000. Mogy Joel R Investment Counsel Inc. bought a new position in shares of Prothena during the 2nd quarter valued at $126,000. Siren L.L.C. lifted its holdings in shares of Prothena by 16.7% during the 1st quarter. Siren L.L.C. now owns 1,283,555 shares of the biotechnology company’s stock valued at $15,884,000 after buying an additional 183,715 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Prothena during the 1st quarter valued at $230,000. 97.08% of the stock is owned by institutional investors.

Prothena Stock Performance

Shares of PRTA stock opened at $10.54 on Wednesday. Prothena Corporation plc has a 52-week low of $4.32 and a 52-week high of $18.88. The firm has a market capitalization of $567.37 million, a PE ratio of -1.87 and a beta of -0.11. The stock has a fifty day simple moving average of $9.17 and a two-hundred day simple moving average of $7.75.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.75). Prothena had a negative return on equity of 62.17% and a negative net margin of 2,929.30%.The business had revenue of $4.42 million during the quarter, compared to analysts’ expectations of $5.36 million. On average, sell-side analysts forecast that Prothena Corporation plc will post -4.04 EPS for the current fiscal year.

Analyst Ratings Changes

PRTA has been the subject of several analyst reports. UBS Group set a $36.00 price objective on Prothena in a research note on Tuesday. Piper Sandler upped their price objective on Prothena from $15.00 to $36.00 and gave the stock an “overweight” rating in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Prothena in a research note on Wednesday, October 8th. Chardan Capital restated a “buy” rating and issued a $18.00 price objective on shares of Prothena in a research note on Thursday, August 28th. Finally, JMP Securities reduced their price objective on Prothena from $29.00 to $11.00 and set a “market outperform” rating for the company in a research note on Tuesday, September 2nd. Four analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Prothena currently has a consensus rating of “Hold” and an average price target of $24.56.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.